ECSP10010705A - Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa - Google Patents

Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa

Info

Publication number
ECSP10010705A
ECSP10010705A EC2010010705A ECSP10010705A ECSP10010705A EC SP10010705 A ECSP10010705 A EC SP10010705A EC 2010010705 A EC2010010705 A EC 2010010705A EC SP10010705 A ECSP10010705 A EC SP10010705A EC SP10010705 A ECSP10010705 A EC SP10010705A
Authority
EC
Ecuador
Prior art keywords
rho
isoquinolinonas
isoquinolinas
quinasa
inhibitors
Prior art date
Application number
EC2010010705A
Other languages
English (en)
Inventor
Oliver Plettenburg
Heinz-Werner Kleemann
Katrin Lorenz
Olivier Duclos
Matthias Loehn
John Weston
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP10010705A publication Critical patent/ECSP10010705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)

Abstract

La invención se refiere a isoquinolinas e isoquinolinonas sustituidas de la fórmula (I)(I)útiles para el tratamiento y/o prevención de enfermedades asociadas con la Rho-quinasa y/o la fosforilación mediada por la Rho-quinasa de la fosfatasa de miosina de cadena ligera, y a composiciones que contienen dichos compuestos.
EC2010010705A 2008-06-24 2010-12-22 Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa ECSP10010705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290606 2008-06-24
US15314909P 2009-02-17 2009-02-17

Publications (1)

Publication Number Publication Date
ECSP10010705A true ECSP10010705A (es) 2011-01-31

Family

ID=40049863

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010705A ECSP10010705A (es) 2008-06-24 2010-12-22 Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa

Country Status (33)

Country Link
US (1) US8541449B2 (es)
EP (1) EP2303846B1 (es)
JP (1) JP5713893B2 (es)
KR (1) KR101638326B1 (es)
CN (1) CN102131784B (es)
AR (1) AR072281A1 (es)
AU (1) AU2009262517B2 (es)
BR (1) BRPI0914696A2 (es)
CA (1) CA2728137C (es)
CO (1) CO6321250A2 (es)
CR (1) CR11831A (es)
DK (1) DK2303846T3 (es)
DO (1) DOP2010000394A (es)
EC (1) ECSP10010705A (es)
ES (1) ES2541827T3 (es)
HK (1) HK1158644A1 (es)
HR (1) HRP20150726T1 (es)
HU (1) HUE026617T2 (es)
IL (1) IL210113A (es)
MA (1) MA32400B1 (es)
MX (1) MX2010013975A (es)
MY (1) MY157330A (es)
NZ (1) NZ590070A (es)
PE (1) PE20110059A1 (es)
PL (1) PL2303846T3 (es)
PT (1) PT2303846E (es)
RU (1) RU2538588C2 (es)
SI (1) SI2303846T1 (es)
SV (1) SV2010003772A (es)
TW (1) TWI462907B (es)
UY (1) UY31925A (es)
WO (1) WO2009156100A1 (es)
ZA (1) ZA201008119B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156099A1 (en) * 2008-06-24 2009-12-30 Sanofi-Aventis 6-substituted isoquinolines and isoquinolinones
EP2733141B1 (en) 2011-07-15 2019-01-09 Shionogi & Co., Ltd. Azabenzimidazole derivative having ampk-activating activity
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113715A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2015042243A1 (en) 2013-09-19 2015-03-26 Bristol-Myers Squibb Company Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6883173B2 (ja) 2015-05-12 2021-06-09 ヘモストッド エスエー 改善された血小板産生のための薬理学的特徴およびマイクロ流体特徴の組み合わせ
WO2018228452A1 (zh) 2017-06-16 2018-12-20 成都先导药物开发有限公司 一种抑制 rock 的化合物及其用途
CN109810174B (zh) * 2017-11-21 2021-01-01 首都医科大学 异喹啉-3-甲酰-TARGD(aa)aa,其制备,抗静脉血栓活性和应用
CN110317169B (zh) * 2018-03-29 2022-06-03 复旦大学 一种1-取代异喹啉酮化合物及其制备方法
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702600A1 (de) * 1977-01-22 1978-07-27 Thomae Gmbh Dr K Neue aminoalkoxyphenyl-derivate
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 選択されたハロカーボンの触媒平衡化
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0956865B2 (en) 1996-08-12 2010-08-18 Mitsubishi Tanabe Pharma Corporation MEDICINES COMPRISING Rho KINASE INHIBITOR
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
EP1007525A1 (en) 1997-08-29 2000-06-14 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
AU779442B2 (en) 2000-01-20 2005-01-27 Eisai Co. Ltd. Novel piperidine compounds and drugs containing the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (en) 2000-02-29 2001-09-07 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2002100833A1 (fr) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
EP2014291B1 (en) * 2001-08-24 2011-10-26 Yale University Piperazinone compounds as anti-tumor and anti-cancer agents
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
WO2004024717A1 (ja) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004113297A2 (en) 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2539814C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030130A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PL1899322T3 (pl) * 2005-06-28 2010-02-26 Sanofi Aventis Pochodne izochinoliny jako inhibitory kinazy Rho
CN101228132B (zh) * 2005-07-26 2012-10-10 塞诺菲-安万特股份有限公司 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物
WO2007012421A1 (en) 2005-07-26 2007-02-01 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
ATE505458T1 (de) * 2006-12-27 2011-04-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
BRPI0721180A2 (pt) * 2006-12-27 2014-03-18 Sanofi Aventis Derivados de isoquinolina substituídos com cicloalquilamina
BRPI0720859A2 (pt) * 2006-12-27 2014-03-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina
PT2132194E (pt) 2006-12-27 2011-05-16 Sanofi Aventis Isoquinolinas substitu?das e sua utiliza??o como inibidores de rho-cinase
CA2673916C (en) * 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase
RU2009128693A (ru) * 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные производные изохинолина и изохинолинона
MX2009005966A (es) * 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolona sustituidos con cicloalquilamina.

Also Published As

Publication number Publication date
DOP2010000394A (es) 2011-01-15
AU2009262517A1 (en) 2009-12-30
SV2010003772A (es) 2011-03-15
HUE026617T2 (en) 2016-06-28
IL210113A0 (en) 2011-02-28
US8541449B2 (en) 2013-09-24
US20110190341A1 (en) 2011-08-04
JP2011525511A (ja) 2011-09-22
TW201010978A (en) 2010-03-16
RU2538588C2 (ru) 2015-01-10
HK1158644A1 (en) 2012-07-20
BRPI0914696A2 (pt) 2016-10-18
ES2541827T3 (es) 2015-07-27
TWI462907B (zh) 2014-12-01
AR072281A1 (es) 2010-08-18
MX2010013975A (es) 2011-01-14
HRP20150726T1 (hr) 2015-09-25
UY31925A (es) 2010-01-29
PT2303846E (pt) 2015-09-04
PE20110059A1 (es) 2011-02-15
DK2303846T3 (en) 2015-08-03
CO6321250A2 (es) 2011-09-20
NZ590070A (en) 2012-02-24
CN102131784B (zh) 2014-08-27
CN102131784A (zh) 2011-07-20
SI2303846T1 (sl) 2015-08-31
CR11831A (es) 2011-03-18
EP2303846B1 (en) 2015-04-29
IL210113A (en) 2015-10-29
PL2303846T3 (pl) 2015-10-30
MY157330A (en) 2016-05-31
RU2011102456A (ru) 2012-07-27
KR20110021922A (ko) 2011-03-04
CA2728137C (en) 2016-10-18
WO2009156100A1 (en) 2009-12-30
JP5713893B2 (ja) 2015-05-07
MA32400B1 (fr) 2011-06-01
CA2728137A1 (en) 2009-12-30
EP2303846A1 (en) 2011-04-06
KR101638326B1 (ko) 2016-07-12
AU2009262517B2 (en) 2014-01-09
ZA201008119B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
ECSP10010705A (es) Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
ECSP099466A (es) Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa
CR9604A (es) Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa
CR9603A (es) Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
ECSP099468A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
ECSP099469A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
ECSP099470A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
DOP2009000164A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
SV2009003317A (es) Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa
UY29641A1 (es) Derivados de isoquinolina
CO6321249A2 (es) Isoquinolinas e isoquinolinonas 6-sustituidas
ECSP10010706A (es) Isoquinolinas e isoquinolinonas 6-sustituidas
UY30841A1 (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
UY29698A1 (es) Derivados de ciclohexilaminisoquinolona
DOP2009000153A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
DOP2009000154A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
TN2010000589A1 (en) Substituted dsoquinolines and isoquinodlinones as rho kinase inhibitors